Litcius/Paper detail

45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Yasutoshi Kuboki, R. Yaeger, M. Fakih, J.H. Strickler, T. Masuishi, E.J-H. Kim, C.M. Bestvina, C.J. Langer, John C. Krauss, S. Puri, P. Cardona, E.K. Chang, Q. Tran, Dehan Hong

2022Annals of Oncology19 citationsDOI

Topics & Concepts

MedicinePanitumumabKRASColorectal cancerCohortRefractory (planetary science)OncologyInternal medicineCancerAstrobiologyPhysicsColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerGastric Cancer Management and Outcomes
45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort | Litcius